## Giuseppe Cimino

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6119034/publications.pdf

Version: 2024-02-01

147 papers 6,858 citations

38 h-index 80 g-index

147 all docs

147 docs citations

times ranked

147

6572 citing authors

#	Article	IF	Citations
1	The t(4;11) chromosome translocation of human acute leukemias fuses the ALL-1 gene, related to Drosophila trithorax, to the AF-4 gene. Cell, 1992, 71, 701-708.	28.9	821
2	Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia. Blood, 2011, 118, 6521-6528.	1.4	395
3	Epigenetic Silencing of the Myelopoiesis Regulator microRNA-223 by the AML1/ETO Oncoprotein. Cancer Cell, 2007, 12, 457-466.	16.8	373
4	Biological and therapeutic aspects of infant leukemia. Blood, 2000, 96, 24-33.	1.4	358
5	Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome–positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007. 109. 3676-3678.	1.4	336
6	Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. Blood, 2010, 116, 3171-3179.	1.4	290
7	<i>IKZF1</i> (Ikaros) Deletions in <i>BCR-ABL1</i> i>–Positive Acute Lymphoblastic Leukemia Are Associated With Short Disease-Free Survival and High Rate of Cumulative Incidence of Relapse: A GIMEMA AL WP Report. Journal of Clinical Oncology, 2009, 27, 5202-5207.	1.6	276
8	Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood, 2004, 104, 1995-1999.	1.4	225
9	A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. Blood, 2005, 105, 3434-3441.	1.4	178
10	Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4 : 11) abnormality. Oncogene, 2001, 20, 874-878.	5.9	154
11	Polycombs and microRNA-223 regulate human granulopoiesis by transcriptional control of target gene expression. Blood, 2012, 119, 4034-4046.	1.4	139
12	Cloning of ALL-1, the locus involved in leukemias with the $t(4;11)(q21;q23)$ , $t(9;11)(p22;q23)$ , and $t(11;19)(q23;p13)$ chromosome translocations. Cancer Research, 1991, 51, 6712-4.	0.9	136
13	Sequential Valproic Acid/All-trans Retinoic Acid Treatment Reprograms Differentiation in Refractory and High-Risk Acute Myeloid Leukemia. Cancer Research, 2006, 66, 8903-8911.	0.9	125
14	ALL-1 gene at chromosome 11q23 is consistently altered in acute leukemia of early infancy. Blood, 1993, 82, 544-546.	1.4	109
15	Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. Blood, 2006, 107, 473-479.	1.4	109
16	Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features. Leukemia, 2007, 21, 79-83.	7.2	108
17	Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. Blood, 1995, 85, 2685-2690.	1.4	107
18	Biological and therapeutic aspects of infant leukemia. Blood, 2000, 96, 24-33.	1.4	102

#	Article	IF	CITATIONS
19	MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood, 2002, 100, 974-981.	1.4	99
20	Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia. Leukemia, 2005, 19, 628-635.	7.2	85
21	Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis. Haematologica, 2011, 96, 552-557.	3.5	84
22	Aspergillus Galactomannan Enzyme-Linked Immunosorbent Assay Cross-Reactivity Caused by Invasive Geotrichum capitatum. Journal of Clinical Microbiology, 2006, 44, 3432-3434.	3.9	82
23	Infant acute leukemias show the same biased distribution of ALL1 gene breaks as topoisomerase II related secondary acute leukemias. Cancer Research, 1997, 57, 2879-83.	0.9	82
24	Expression profiles of acute lymphoblastic and myeloblastic leukemias with ALL-1 rearrangements. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 7853-7858.	7.1	73
25	Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols. Blood, 2012, 119, 49-54.	1.4	63
26	Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease. Leukemia, 2015, 29, 1360-1365.	7.2	57
27	Acute leukaemia in patients treated for Hodgkin's disease. British Journal of Haematology, 1984, 58, 43-52.	2.5	55
28	Epigenetic plasticity of chromatin in embryonic and hematopoietic stem/progenitor cells: therapeutic potential of cell reprogramming. Leukemia, 2008, 22, 1503-1518.	7.2	55
29	Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World Journal of Gastroenterology, 2011, 17, 3881.	3.3	51
30	Cystic Fibrosis: Recent Insights into Inhaled Antibiotic Treatment and Future Perspectives. Antibiotics, 2021, 10, 338.	3.7	50
31	CD1d expression on B-precursor acute lymphoblastic leukemia subsets with poor prognosis. Leukemia, 2005, 19, 551-556.	7.2	49
32	Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia. Haematologica, 2007, 92, 1273-1274.	3.5	49
33	Prognostic relevance of ALL-1 gene rearrangement in infant acute leukemias. Leukemia, 1995, 9, 391-5.	7.2	47
34	ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. Blood, 2007, 109, 5473-5476.	1.4	46
35	Anti-CD20 Therapy Acts via FcγRIIIA to Diminish Responsiveness of Human Natural Killer Cells. Cancer Research, 2015, 75, 4097-4108.	0.9	46
36	ALL-1 gene rearrangements in acute myeloid leukemia: association with M4-M5 French-American-British classification subtypes and young age. Cancer Research, 1995, 55, 1625-8.	0.9	42

#	Article	IF	CITATIONS
37	Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. American Journal of Hematology, 2017, 92, 187-195.	4.1	41
38	Clinical relevance of residual disease monitoring by polymerase chain reaction in patients with ALLâ€1/AFâ€4 positiveâ€acute lymphoblastic leukaemia. British Journal of Haematology, 1996, 92, 659-664.	2.5	39
39	Clinico-biologic features and treatment outcome of adult pro-B-ALL patients enrolled in the GIMEMA 0496 study: absence of the ALL1/AF4 and of the BCR/ABL fusion genes correlates with a significantly better clinical outcome. Blood, 2003, 102, 2014-2020.	1.4	38
40	Comorbidities and FLT3â€ITD abnormalities as independent prognostic indicators of survival in Elderly acute myeloid leukaemia patients. Hematological Oncology, 2009, 27, 148-153.	1.7	38
41	MOPP chemotherapy versus extended-field radiotherapy in the management of pathological stages I-IIA Hodgkin's disease Journal of Clinical Oncology, 1989, 7, 732-737.	1.6	37
42	Do malignant diseases affect semen quality? Sperm parameters of men with cancers. Andrologia, 2016, 48, 333-340.	2.1	37
43	CIZ gene rearrangements in acute leukemia: report of a diagnostic FISH assay and clinical features of nine patients. Leukemia, 2005, 19, 1696-1699.	7.2	36
44	An altered $11$ -kilobase transcript in leukemic cell lines with the t(4;11)(q21;q23) chromosome translocation. Cancer Research, 1992, 52, 3811-3.	0.9	36
45	A multiplex reverse transcriptase-polymerase chain reaction strategy for the diagnostic molecular screening of chimeric genes: a clinical evaluation on 170 patients with acute lymphoblastic leukemia. Haematologica, 2003, 88, 275-9.	3.5	36
46	A prospective study of residual-disease monitoring of the ALL1/AF4 transcript in patients with t(4;11) acute lymphoblastic leukemia. Blood, 2000, 95, 96-101.	1.4	35
47	Subclinical Anthracycline Cardiotoxicity in Patients With Acute Promyelocytic Leukemia in Longâ€∓erm Remission After the AIDA Protocol. Congestive Heart Failure, 2012, 18, 217-221.	2.0	33
48	Thrombosis and survival in essential thrombocythemia: A regional study of 1,144 patients. American Journal of Hematology, 2014, 89, 542-546.	4.1	33
49	The role of BCR/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia: a seven-year update of the GIMEMA 0496 trial. Haematologica, 2006, 91, 377-80.	3.5	32
50	Recovery of Chronic Renal Impairment With Sirolimus After Lung Transplantation. Annals of Thoracic Surgery, 2004, 78, 1940-1943.	1.3	31
51	Single Daily Dose Ceftriaxone Plus Amikacin Treatment of Febrile Episodes in Neutropenic Patients Attending Day Hospital for Hematologic Malignancies. Oncology, 1992, 49, 49-52.	1.9	30
52	Sequential molecular monitoring of chimerism in chronic myeloid leukemia patients receiving donor lymphocyte transfusion for relapse after bone marrow transplantation. Bone Marrow Transplantation, 1997, 19, 703-707.	2.4	30
53	Front-Line Treatment of Acute Promyelocytic Leukemia with AIDA Induction Followed by Risk-Adapted Consolidation: Results of the AIDA-2000 Trial of the Italian GIMEMA Group Blood, 2004, 104, 392-392.	1.4	30
54	ALL-1 gene at chromosome 11q23 is consistently altered in acute leukemia of early infancy. Blood, 1993, 82, 544-546.	1.4	30

#	Article	IF	Citations
55	Sequential Combination Chemotherapy of High-Grade Non-Hodgkin's Lymphoma with 5-Fluorouracil, Methotrexate, Cytosine-Arabinoside, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (F-MACHOP). Cancer Investigation, 1987, 5, 159-169.	1.3	29
56	A Genotypic-Oriented View of CFTR Genetics Highlights Specific Mutational Patterns Underlying Clinical Macrocategories of Cystic Fibrosis. Molecular Medicine, 2015, 21, 257-275.	4.4	29
57	t(4;11)(q21;p15) translocation involving NUP98 and RAP1GDS1 genes: characterization of a new subset of T acute lymphoblastic leukaemia. British Journal of Haematology, 2000, 109, 788-793.	2.5	28
58	Evaluation of a home telemonitoring service for adult patients with cystic fibrosis: a pilot study. Journal of Telemedicine and Telecare, 2010, 16, 359-362.	2.7	28
59	Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients. American Journal of Hematology, 2016, 91, 318-321.	4.1	28
60	Arterial and venous thrombosis in patients with monoclonal gammopathy of undetermined significance: incidence and risk factors in a cohort of 1491 patients. British Journal of Haematology, 2013, 160, 673-679.	2.5	23
61	Effects of hydration with salt repletion on renal toxicity of conventional amphotericin B empirical therapy: a prospective study in patients with hematological malignancies. Supportive Care in Cancer, 2005, 13, 987-992.	2.2	22
62	GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Longâ€ŧerm results and prognostic factors. British Journal of Haematology, 2011, 154, 564-568.	2.5	22
63	Tapentadol prolonged release for patients with multiple myeloma suffering from moderate-to-severe cancer pain due to bone disease. Journal of Pain Research, 2015, 8, 229.	2.0	22
64	Immune-deficiency in Hodgkin's disease (HD): a study of patients and healthy relatives in families with multiple cases. European Journal of Cancer & Clinical Oncology, 1988, 24, 1595-1601.	0.7	19
65	Evaluation of therapeutic modalities in the control of hodgkin's disease. International Journal of Radiation Oncology Biology Physics, 1986, 12, 1617-1620.	0.8	18
66	Late Relapses in Acute Promyelocytic Leukaemia. Acta Haematologica, 2007, 117, 106-108.	1.4	17
67	Clinical and biological features of acute promyelocytic leukemia patients developing retinoic acid syndrome during induction treatment with all-trans retinoic acid and idarubicin. Haematologica, 2008, 93, 1918-1920.	3.5	17
68	Antiviral treatment including entecavir plus tenofovir disoproxil fumarate for HBV reactivation following a rituximab-based regimen. Antiviral Therapy, 2010, 15, 929-932.	1.0	17
69	Efficacy of Extracorporeal Photopheresis in Patients With Bronchiolitis Obliterans Syndrome After Lung Transplantation. Transplantation Proceedings, 2017, 49, 695-698.	0.6	17
70	Dasatinib as Front-Line Monotherapy for the Induction Treatment of Adult and Elderly Ph+ Acute Lymphoblastic Leukemia (ALL) Patients: Interim Analysis of the GIMEMA Prospective Study LAL1205 Blood, 2007, 110, 7-7.	1.4	16
71	p53 gene inactivation in acute lymphoblastic leukemia of B cell lineage associates with chromosomal breakpoints at 11q23 and 8q24. Leukemia, 1995, 9, 955-9.	7.2	16
72	Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form. Cancer, 2012, 118, 5544-5549.	4.1	15

#	Article	IF	Citations
73	Acute promyelocytic leukemia in patients aged >70Âyears: the cure beyond the age. Annals of Hematology, 2015, 94, 195-200.	1.8	15
74	Interstitial Insertion of AF10 into the ALL1 Gene in a Case of Infant Acute Lymphoblastic Leukemia. Cancer Genetics and Cytogenetics, 1998, 107, 107-110.	1.0	14
75	Identification and monitoring of atypicalPML/RARAfusion transcripts in acute promyelocytic leukemia. Genes Chromosomes and Cancer, 2019, 58, 60-65.	2.8	14
76	Assessment of Resistance Mechanisms and Clinical Implications in Patients with KRAS Mutated-Metastatic Breast Cancer and Resistance to CDK4/6 Inhibitors. Cancers, 2021, 13, 1928.	3.7	14
77	Chemotherapy versus radiotherapy in early-stage Hodgkin's disease: Evidence of a more difficult rescue for patients relapsed after chemotherapy. European Journal of Cancer, 1992, 28, 1853-1855.	2.8	13
78	Analysis of the BCL-6 gene configuration in diffuse B-cell non-Hodgkin's lymphomas and Hodgkin's disease. Journal of Pathology, 1995, 177, 21-25.	4.5	13
79	The therapeutic response and clinical outcome of adults with ALL1(MLL)/AF4 fusion positive acute lymphoblastic leukemia according to the GIMEMA experience. Haematologica, 2010, 95, 837-840.	3.5	12
80	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a realâ€world setting. A GIMEMAâ€ERIC and US study. Cancer Medicine, 2020, 9, 8468-8479.	2.8	12
81	Hemoglobin levels and circulating blasts are two easily evaluable diagnostic parameters highly predictive of leukemic transformation in primary myelofibrosis. Leukemia Research, 2015, 39, 314-317.	0.8	11
82	PD-L1 Expression on Circulating Tumour Cells May Be Predictive of Response to Regorafenib in Patients Diagnosed with Chemorefractory Metastatic Colorectal Cancer. International Journal of Molecular Sciences, 2020, 21, 6907.	4.1	11
83	Multigenetic lesions in infant acute leukaemias: correlations with ALL-1 gene status. British Journal of Haematology, 1997, 96, 308-313.	2.5	10
84	Dramatic Improvement in CR Rate and CR Duration with Imatinib in Adult and Elderly Ph+ ALL Patients: Results of the GIMEMA Prospective Study LAL0201 Blood, 2004, 104, 2739-2739.	1.4	10
85	Chemotherapy alone for the treatment of early-stage Hodgkin's disease. European Journal of Cancer & Clinical Oncology, 1990, 26, 1115-1118.	0.7	9
86	Distribution of TP53 mutations among acute leukemias with MLL rearrangements., 1996, 15, 48-53.		9
87	A case of Burkitt lymphoma â€" L <sub>3</sub> ALL with t(8;14) translocation, developed 10 years after Hodgkin's disease. Scandinavian Journal of Haematology, 1985, 34, 97-100.	0.0	9
88	High platelet count at diagnosis is a protective factor for thrombosis in patients with essential thrombocythemia. Thrombosis Research, 2017, 156, 168-171.	1.7	9
89	Genetic lesions disrupting calreticulin 3′â€untranslated region in <scp>JAK2</scp> mutationâ€negative polycythemia <scp>vera</scp> . American Journal of Hematology, 2020, 95, E263.	4.1	9
90	Herpes zoster granulomatous dermatitis in metastatic lung cancer treated with nivolumab: A case report. Thoracic Cancer, 2020, 11, 1330-1333.	1.9	9

#	Article	IF	CITATIONS
91	Elexacaftor/tezacaftor/ivacaftor in children aged 6–11 years with cystic fibrosis, at least one <i>&gt;F508DEL</i> allele, and advanced lung disease: A 24â€week observational study. Pediatric Pulmonology, 2022, 57, 2253-2256.	2.0	9
92	Idarubicin intensified BUCY2 regimen in allogeneic unmanipulated transplant for high-risk hematological malignancies. Leukemia, 2000, 14, 2052-2058.	<b>7.</b> 2	8
93	Negative impact of FLT3 abnormalities in elderly acute myeloid leukemia patients. Leukemia and Lymphoma, 2008, 49, 994-997.	1.3	8
94	No detection of SARS-CoV-2 in cystic fibrosis patients at the Regional (Lazio) Reference Center for CF in Italy. Journal of Cystic Fibrosis, 2020, 19, 837-838.	0.7	8
95	Myeloperoxidase gene expression in non-infant pro-B acute lymphoblastic leukaemia with or without ALL1/AF4 transcript. British Journal of Haematology, 2000, 111, 1065-1070.	2.5	8
96	ALL-1 gene at chromosome 11q23 is consistently altered in acute leukemia of early infancy. Blood, 1993, 82, 544-6.	1.4	8
97	Trisomy 13 in a patient with common acute lymphoblastic leukemia: description of a case and review of the literature. Cancer Genetics and Cytogenetics, 2003, 144, 69-72.	1.0	7
98	BAVC regimen and autologous bone marrow transplantation for APL patients in second molecular remission: updated results. Bone Marrow Transplantation, 2005, 36, 83-84.	2.4	7
99	Improving outcomes of acute invasive Aspergillus rhinosinusitis n patients with hematologici malignancies or aplastic anemia: the role of voriconazole. Haematologica, 2008, 93, 159-160.	3.5	6
100	Comparison of 18F FDG PET-CT AND CECT in pretreatment staging of adults with Hodgkin's lymphoma. Leukemia Research, 2019, 76, 48-52.	0.8	6
101	miR‑125b/NRF2/HO‑1 axis is involved in protection against oxidative stress of cystic fibrosis: A pilot study. Experimental and Therapeutic Medicine, 2021, 21, 585.	1.8	6
102	Risk factors for nephrotoxicity associated with conventional amphotericin B therapy. American Journal of Medicine, 2002, 113, 351.	1.5	5
103	Repeated rituximab maintenance courses in fludarabine-failed young patients with chronic lymphocytic leukaemia responding to FAND chemotherapy. The Hematology Journal, 2004, 5, 186-187.	1.4	5
104	Retrospective comparison of qualitative and quantitative reverse transcriptase polymerase chain reaction in diagnosing and monitoring the ALL1-AF4 fusion transcript in patients with acute lymphoblastic leukaemia. Leukemia, 2004, 18, 1824-1830.	7.2	5
105	Solitary plasmacytoma of tibia: A possible correlation with younger age. Leukemia Research, 2010, 34, e181-e182.	0.8	5
106	Hepatitis B reactivation despite entecavir prophylaxis in a patient with chronic lymphocytic leukaemia receiving bendamustine. Journal of Antimicrobial Chemotherapy, 2012, 67, 510-511.	3.0	5
107	Burkholderia pyrrocinia in Cystic Fibrosis Lung Transplantation: AÂCase Report. Transplantation Proceedings, 2014, 46, 295-297.	0.6	5
108	A highly specific q-RT-PCR assay to address the relevance of the JAK2WT and JAK2V617F expression levels and control genes in Ph-negative myeloproliferative neoplasms. Annals of Hematology, 2014, 93, 609-616.	1.8	5

#	Article	IF	CITATIONS
109	Synchronous and Metachronous Metastatic Breast Cancer, with Different Histology and Opposite Immunophenotype, Treated with Combination of Chemotherapy, Anti-Her2, and Endocrine Therapy: A Case Report. Case Reports in Oncology, 2020, 13, 544-549.	0.7	5
110	MLL tandem duplication in two cases of acute myelocytic leukemia with unbalanced translocations. Cancer Genetics and Cytogenetics, 2003, 142, 8-12.	1.0	4
111	Clinical outcome and monitoring of minimal residual disease in patients with acute lymphoblastic leukemia expressing the <i>MLL/ENL</i> fusion gene. American Journal of Hematology, 2011, 86, 993-997.	4.1	4
112	Alectinib in the treatment of ocular metastases of ALK rearranged non small cell lung cancer. Medicine (United States), 2020, 99, e21004.	1.0	4
113	Differential toll like receptor expression in cystic fibrosis patients' airways during rhinovirus infection. Journal of Infection, 2020, 81, 726-735.	3.3	4
114	SARS-CoV-2 Entry Genes Expression in Relation with Interferon Response in Cystic Fibrosis Patients. Microorganisms, 2021, 9, 93.	3.6	4
115	Detection of BCR/ABL rearrangements in adult acute lymphoblastic leukemia using a highly sensitive interphase fluorescence in situ hybridization method (D-FISH). The Hematology Journal, 2001, 2, 54-60.	1.4	4
116	Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Already Harbor Bcr-Abl Kinase Domain Mutations at Low Levels at the Time of Diagnosis - a Report by the GIMEMA ALL Working Party. Blood, 2008, 112, 722-722.	1.4	4
117	Biological and therapeutic aspects of infant leukemia. Blood, 2000, 96, 24-33.	1.4	4
118	Intracardiac Thrombus in a Patient with Autoimmune Hemolytic Anemia Leading to a Diagnosis of Antiphospholipid Syndrome. Acta Haematologica, 2002, 107, 170-172.	1.4	3
119	A POPULATION-BASED STUDY ON MYELODYSPLASTIC SYNDROMES IN THE LAZIO REGION (ITALY), MEDICAL MISCODING AND 11-YEAR MORTALITY FOLLOW-UP: THE GRUPPO ROMANO-LAZIALE MIELODISPLASIE EXPERIENCE OF RETROSPECTIVE MULTICENTRIC REGISTRY. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 9, e2017046.	1.3	3
120	Stunning Response with Low-Dose Enzalutamide after Abiraterone Acetate Failure in a Patient Diagnosed with Metastatic Castration-Resistant Prostate Cancer: A Case Report. Case Reports in Oncology, 2021, 14, 634-640.	0.7	3
121	Prognostic impact of <scp><i>KMT2Aâ€AFF1</i></scp> â€positivity in 926 <scp><i>BCRâ€ABL1</i></scp> â€nega Bâ€lineage acute lymphoblastic leukemia patients treated in <scp>GIMEMA</scp> clinical trials since 1996. American Journal of Hematology, 2021, 96, E334-E338.	itive 4.1	3
122	Early response to caplacizumab and rituximab after anaphylaxis to Octaplas plasma in a patient with thrombotic thrombocytopenic purpura. Journal of Clinical Apheresis, 2021, 36, 499-504.	1.3	3
123	Biclonal blast crisis with a mutated ABL catalytic domain in a Ph, del (9q)-positive CML patient responsive to imatinib: drug resistance should be monitored in all patients irrespective of response status. Leukemia, 2005, 19, 287-289.	7.2	2
124	Haemolytic uremic syndrome during induction therapy in an acute promyelocytic leukemia patient with aberrant phenotype: A possible manifestation of retinoic acid syndrome. Leukemia and Lymphoma, 2007, 48, 833-834.	1.3	2
125	Prolonged molecular remission in a newly diagnosed acute promyelocytic leukaemia with a severe cardiomyopathy using low-dose gemtuzumab ozogamicin and all-trans retinoic acid. Annals of Hematology, 2007, 86, 295-297.	1.8	2
126	An acute promyelocytic leukaemia patient with a new atypical promyelocytic leukemia breakpoint. British Journal of Haematology, 2008, 142, 854-856.	2.5	2

#	Article	IF	Citations
127	Multiple thromboembolism with multiple causes in a 69-year-old woman: a case report. Journal of Medical Case Reports, 2011, 5, 186.	0.8	2
128	Prognostic factors for thrombosis-free survival and overall survival in polycythemia vera: A retrospective analysis of 623 PTS With long follow-up. Leukemia Research, 2018, 69, 18-23.	0.8	2
129	Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols. Acta Oncol $ ilde{A}^3$ gica, 2021, 60, 1520-1526.	1.8	2
130	Daratumumab triplet therapies in patients with relapsed or refractory Multiple Myeloma: a "real world―experience. Leukemia Research Reports, 2022, , 100330.	0.4	2
131	The Role of Restaging Laparotomy in Hodgkin'S Disease. Acta Oncológica, 1989, 28, 659-662.	1.8	1
132	Molecular cytogenetics characterization of a novel translocation involving chromosomes 17 and 19 in a Ph+ adult acute lymphoblastic leukaemia. British Journal of Haematology, 2002, 119, 488-491.	2.5	1
133	Increasing the BCR-ABL expression levels and/or the occurrence of ABL point mutations does not always predict resistance to Imatinib Mesylate in BCR-ABL positive acute lymphoblastic leukemia. Leukemia Research, 2009, 33, e73-e74.	0.8	1
134	<i>àẽReal Life'</i> experience in a â€̃ <i>difficult to treat'</i> patient population of non-Hodgkin lymphousing the R-COMP regimen. Leukemia and Lymphoma, 2016, 57, 2919-2922.	mas 1.3	1
135	Hodgkin lymphoma in pregnancy: good news for clinicians and women. Lancet Haematology,the, 2019, 6, e541-e542.	4.6	1
136	Acute Promyelocytic Leukemia After Radium-223 Exposure for Prostate Cancer in a Chemotherapy-NaÃ <sup>-</sup> ve Patient. Nuclear Medicine and Molecular Imaging, 2020, 54, 256-260.	1.0	1
137	Valproic Acid Plus Retinoic Acid Induce Myeloid Differentiation in Chemotherapy-Resistant Acute Myeloid Leukemia Patients Blood, 2004, 104, 1805-1805.	1.4	1
138	Role of PET/CT in the Diagnostic Work-up of Patients with Chronic Lymphocytic Leukemia (CLL) and Clinical Signs of Disease Progression. Blood, 2012, 120, 3888-3888.	1.4	1
139	Acute Promyelocytic Leukemia (APL) in Very Elderly Patients: Real-Life behind Protocols. Blood, 2019, 134, 3845-3845.	1.4	1
140	Astonishing response to Cetuximab in metastatic nasopharyn- geal carcinoma: a case report. Clinica Terapeutica, 2021, 172, 260-263.	0.3	1
141	PrecipitatingPseudomonas aeruginosa antibodies and antimicrobial therapy in cystic fibrosis patients. European Journal of Clinical Microbiology and Infectious Diseases, 1996, 15, 309-312.	2.9	0
142	Patients with classical Hodgkin lymphoma (CHL) and treatment failure despite a negative iPET have poor outcomes as patients with positive iPET and treatment escalation. Hematological Oncology, 2017, 35, 313-315.	1.7	0
143	Unexpected cause of pancytopenia in a teenager with Noonan syndrome. EJHaem, 2021, 2, 642-643.	1.0	0
144	ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS AGED > 70 Years Blood, 2009, 114, 4160-4160.	1.4	0

#	Article	IF	CITATIONS
145	The Role of Previous Thrombotic Events in Patients with Essential Thrombocythemia: The Earlier the Worse?. Blood, 2012, 120, 5062-5062.	1.4	O
146	Immunotherapy in Multiple Myeloma: Experience of the Multiple Myeloma Gimema Lazio Group. Blood, 2018, 132, 5634-5634.	1.4	0
147	Geographic distribution and phenotype of European people with cystic fibrosis carrying A1006E mutation. Respiratory Medicine, 2022, 192, 106736.	2.9	0